https://doi.org/10.1128/iai.00679-21. Epub 2022 Jan 18. PMID: 35099276; PMCID: PMC8929341.

Meynard, J.L., Meyohas, M.C., Binet, D., Chouaid, C., Frottier, J., 1996. Pulmonary cryptosporidiosis in the acquired immunodeficiency syndrome. Infection 24 (4), 328-331. https://doi.org/10.1016/BF01743372. PMID: 8875287.

Miller, C.N., Jossé, L., Brown, I., Blakeman, B., Povey, L., Yiangou, L., Price, M., Cinatl Jr., J., Xue, W.F., Michaelis, M., Tsaouisi, A.D., 2018. A cell culture platform for Cryptosporidium that enables long-term cultivation and new tools for the systematic investigation of its biology. Int. J. Parasitol. 48 (3-4), 197-201. https://doi.org/10.1016/j.ijpara.2017.10.001. PMID: 20195082; PMCID: PMC5854368.

Morada, M., Lee, S., Gunther-Cummins, L., Weiss, L.M., Widmer, G., Tzironi, S., Yarlett, N., 2016. Continuous culture of Cryptosporidium parvum using hollow fiber technology. Int. J. Parasitol. 46 (1), 21-29. https://doi.org/10.1016/j.ijpara.2015.07.006. Epub 2015 Sep 2. PMID: 26341006.

Murakoshi, F., Bando, H., Sugi, T., Adeyemi, O.S., Nonaka, M., Nakaya, T., Kato, K., 2020. Nullscript inhibits cryptosporidium and Toxoplasma growth. Int J Parasitol Drugs Drug Resist 14, 159-166. https://doi.org/10.1016/j.ijddr.2020.10.004. Epub 2020 Oct 15. PMID: 33120250; PMCID: PMC7593347.

Nava, M.G., Calderón, F., Fernández, E., Ballell, L., Bamborough, P., Vinayak, S., 2023. Tyrosine kinase inhibitors display potent activity against *Cryptosporidium parvum*. Microbiol. Spectr. 11 (1), e38422 https://doi.org/10.1128/spectrum.03874-22. Epub 2022 Dec 19. PMID: 36533912; PMCID: PMC9927415.

Oboh, E., Schubert, T.J., Teixeira, J.E., Stebbins, E.E., Miller, P., Philo, E., Thakellapalli, H., Campbell, S.D., Griggs, D.W., Huston, C.D., Meyers, M.J., 2021. Optimization of the urea linker of triazolopyridazine MMV665917 results in a new anticryptosporidial lead with improved potency and predicted hERG safety margin. J. Med. Chem. 64 (15), 11729-11745. https://doi.org/10.1021/acs.jmchem.1c01136. Epub 2021 Aug 3. PMID: 34342443; PMCID: PMC8792988.

Oboh, E., Teixeira, J.E., Schubert, T.J., Maribona, A.S., Denman, B.N., Patel, R., Huston, C.D., Meyers, M.J., 2023. Structure-Activity relationships of replacements for the triazolopyridazine of Anti-*Cryptosporidium* lead SLU-2633. Bioorg. Med. Chem. 86, 117295 https://doi.org/10.1016/j.bmc.2023.117295. Epub 2023 Apr 28. PMID: 37148788; PMID: PMC10201403.

O'Connor, R.M., Nepveux, V.F.J., Abenoja, J., Bowden, G., Reis, P., Beaushaw, J., Bone Relat, R.M., Driskell, I., Gimenez, F., Riggs, M.W., Schaefer, D.A., Schmidt, E.W., Lin, Z., Distel, D.L., Clardy, J., Ramadhar, T.R., Alred, D.R., Fritz, H.M., Rathod, P., Chery, L., White, J., 2020. A symbiotic bacterium of shipworms produces a compound with broad spectrum anti-apicomplexan activity. PLoS Pathog. 16 (5), e1008600 https://doi.org/10.1371/journal.ppat.1008600. PMID: 32453775; PMCID: PMC7274485.

Ojo, K.K., Larson, E.T., Keyloun, K.R., Castaneda, L.J., Derocher, A.E., Inampudi, K.K., Kim, J.E., Arakaki, T.L., Murphy, R.C., Zhang, L., Napuli, A.J., Maly, D.J., Verlinde, C.L., Buckley, F.S., Parsons, M., Hol, W.G., Merritt, E.A., Van Voorhis, W. C., 2010. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat. May 2. Mol. Biol. 17 (5), 602-607. https://doi.org/10.1038/nmb.1818. Epub 2010 May 2. PMID: 20436472; PMCID: PMC28968734.0.

Omolabi, K.F., Iwuchukwu, E.A., Agoni, C., Olotu, F.A., Soliman, M.E.S., 2021. A probable means to an end: exploring P131 pharmacologic scaffold to identify potential inhibitors of *Cryptosporidium* parvum inosine monophosphate dehydrogenase. J. Mol. Model. 27 (2), 35. https://doi.org/10.1007/s00894-020-04663-3. PMID: 3342340.

Pawlowic, M.C., Somepalli, M., Sateriale, A., Herbert, G.T., Gibson, A.R., Cuny, G.D., Hedstrom, L., Striepen, B., 2019. Genetic ablation of purine salvage in Cryptosporidium parvum reveals nucleotide uptake from the host cell. Proc Natl Acad Sci U S A 116 (42), 21160-21165. https://doi.org/10.1073/pnas.1908239116. Epub 2019 Sep 30. PMID: 31570573; PMCID: PMC6800313.

Rider, SD Jr, Zhu, G., 2010. Cryptosporidium: genomic and biochemical features. Exp. Parasitol. 124 (1), 2-9. https://doi.org/10.1016/j.expara.2008.12.014. Epub 2008 Dec 31. PMID: 19187778; PMCID: PMC2819285.

Riordan, C.E., Ault, J.G., Langreth, S.G., Keithly, J.S., 2003. Cryptosporidium parvum Cp60 targets a relict organelle. Curr. Genet. 44 (3), 138-147. doi:10.1007/s00294-003-0432-1. Epub 2003 Aug 20. PMID: 12928750.

Rochelle, P.A., Ferguson, D.M., Johnson, A.M., De Leon, R., 2001. Quantitation of *Cryptosporidium parvum* infection in cell culture using a colorimetric in situ hybridization assay. J. Eukaryot. Microbiol. 48 (5), 565-574. https://doi.org/10.1111/j.1550-7408.2001.tb00192.x. PMID: 11596921.

Ryan, U.M., Feng, Y., Fayer, R., Xiao, L., 2021. Taxonomy and molecular epidemiology of *Cryptosporidium* and *Giardia* – a 50 year perspective (1971-2021). Int. J. Parasitol. 51 (13-14), 1099-1119. https://doi.org/10.1016/j.ijpara.2021.08.007. Epub 2021 Oct 26. PMID: 34715087.

Sarwono, A.E.Y., Mitsuhashi, S., Kabir, M.H.B., Shigetomi, K., Okada, T., Ohsaka, F., Otsuguro, S., Maenaka, K., Igarashi, M., Kato, K., Ubukata, M., 2019. Repurposing existing drugs: identification of irreversible IMPDH inhibitors by high-throughput screening. J Enzyme Inhib Med Chem 34 (1), 171-178. https://doi.org/10.1080/14756366.2018.1540474. PMID: 30451014; PMCID: PMC6249553.

Shigetomi, K., Sarwono, A.E.Y., Ichikawa, S., Ubukata, M., 2019. Novel adenosine-derived inhibitors of *Cryptosporidium parvum* inosine 5'-monophosphate dehydrogenase. J. Antibiot. (Tokyo) 72 (12), 934-942. https://doi.org/10.1038/s41429-019-01993-9. Epub 2019 Jul 12. PMID: 31296916.

Shu, F., Li, Y., Chu, W., Chen, X., Zhang, Z., Guo, Y., Feng, Y., Xiao, L., Li, N., 2022. Characterization of calcium-dependent protein kinase 2A, a potential drug target against cryptosporidiosis. Front. Microbiol. 13, 883674 https://doi.org/10.3389/fmicb.2022.883674. PMID: 35558125; PMCID: PMC9090282.

Stebbins, E., Jumani, R.S., Klopfer, C., Barlow, J., Miller, P., Campbell, M.A., Meyers, M. J., Griggs, D.W., Huston, C.D., 2018. Clinical and microbiologic efficacy of the

piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model. PLoS Negl Trop Dis 12 (1), e0061683. https://doi.org/10.1371/journal.pntd.00061683. PMID: 29309415; PMCID: PMC5774826.

Su, J., Shen, Y., Li, N., Li, Y., Zhang, Z., Xiao, L., Guo, Y., Feng, Y., 2022. Comparative characterization of CpCDPK1 and CpCDPK9, two potential drug targets against cryptosporidiosis. *Microorganisms* 10 (2), 333. https://doi.org/10.3390/microorganisms10020333. PMID: 35208789; PMCID: PMC8875172.

Tandel, J., English, E.D., Sateriale, A., Gullicksrud, J.A., Beiting, D.P., Sullivan, M.C., Pinkston, B., Striepen, B., 2019. Life cycle progression and sexual development of the apicomplexan parasite *Cryptosporidium parvum*. Nat Microbiol 4 (12), 2226-2236. https://doi.org/10.1038/s41564-019-0539-x. Epub 2019 Sep 2. PMID: 31477896; PMCID: PMC6877471.

Teichmann, K., Kuliberda, M., Schatzmayr, G., Hadacek, F., Joachim, A., 2012. *In vitro* determination of anticryptosporidial activity of phytoogenic extracts and compounds. Parasitol. Res. 111 (1), 231-240. https://doi.org/10.1007/s00436-012-2824-y. Epub 2012 Jan 26. PMID: 22278729.

Thelen, K., Dressman, J.B., 2009. Cytochrome P450-mediated metabolism in the human gut wall. J. Pharm. Pharmacol. 61 (5), 541-558. https://doi.org/10.1211/jpp.61.05.0002. PMID: 19405992.

Timmermans, M., Hubers, W., Schroer, D., Gevers, K., Pam Segers, R., Niessen, R., van Roosmalen, M., 2024. The first commercially approved efficacious cryptosporidium vaccine protecting New-Born calves from severe diarrhea. Veterinary Vaccine 3 (1), 100054. https://doi.org/10.1016/j.vetvac.2024.100054. ISSN 2772-5359.

Umejiego, N.N., Li, C., Riera, T., Hedstrom, L., Striepen, B., 2004. Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural, and dynamic properties that can be exploited for drug design. J. Biol. Chem. 279 (39), 40302-40327. https://doi.org/10.1074/jbc.M407121200. Epub 2004 Jul 21. PMID: 15269207.

Vinayak, S., Pawlowic, M.C., Sateriale, A., Brooks, C.F., Studstill, C.J., Bar-Peled, Y., Cipriano, M.J., Striepen, B., 2015. Genetic modification of the diarrhoeal pathogen *Cryptosporidium parvum*. Nature 523 (7561), 477-480. https://doi.org/10.1038/nature14615. Epub 2015 Jul 15. PMID: 26176919; PMCID: PMC4640681.

Vinayak, S., Jumani, R.S., Miller, P., Hasan, M.M., McLeod, B.I., Tandel, J., Stebbins, E. E., Teixeira, J.E., Borrel, J., Gonse, A., Zhang, M., Ma, Yu, X., Wernimont, A., Walpole, C., Eckley, S., Love, M.S., McNamara, C.W., Sharma, M., Sharma, A., Scherer, C.A., Kato, N., Schreiber, S.L., Melillo, B., Striepen, B., Huston, C.D., Comer, E., 2020. Bicyclic azetidines kill the diarrhoeal pathogen *Cryptosporidium* in mice by inhibiting parasite phenylalanyl-tRNA synthetase. Sci. Transl. Med. 12 (563), eab8412 https://doi.org/10.1126/scitranslmed.aba8412. PMID: 32998973; PMCID: PMC8381743.

Wilke, G., Funkhouser-Jones, L.J., Wang, Y., Ravindran, S., Wang, Q., Beatty, W.L., Baldridge, M.T., VanDussen, K.L., Shen, B., Kuhlenschmidt, M.S., Kuhlenschmidt, T. B., Witola, W.H., Stappenbeck, T.S., Sibley, L.D., 2019. A stem-cell-derived platform enables complete cryptosporidium development in vitro and genetic tractability. e Cell Host Microbe 26 (1), 123-134. https://doi.org/10.1016/j.chom.2019.05.007. Epub 2019 Jun 20. PMID: 31231046; PMCID: PMC6617391.

Wilke, G., Wang, Y., Ravindran, S., Stappenbeck, T., Witola, W.H., Sibley, L.D., 2020. In vitro culture of cryptosporidium parvum using stem cell-derived intestinal epithelial monolayers. Methods Mol. Biol. 2052, 351-372. https://doi.org/10.1007/978-1-4939-9748-0_20. PMID: 31452172.

Wittenberg, D.F., Miller, N.M., van den Ende, J., 1989. Spiramycin is not effective in treating cryptosporidium diarrhea in infants: results of a double-blind randomized trial. J. Infect. Dis. 159 (1), 131-132. https://doi.org/10.1093/infdis/159.1.131. PMID: 2642518.

Xu, R., Beatty, W.L., Greigert, V., Witola, W.H., Sibley, L.D., 2024. Multiple pathways for glucose phosphate transport and utilization support development of Cryptosporidium parvum. Nat. Commun. 15 (1), 380. https://doi.org/10.1038/s41467-024-44696-3. PMID: 38191884; PMCID: PMC10774378.

Yu, Y., Zhang, H., Guo, F., Sun, M., Zhu, G., 2014. A unique hexokinase in Cryptosporidium parvum, an apicomplexan pathogen lacking the Krebs cycle and oxidative phosphorylation. Protist 165 (5), 701-714. https://doi.org/10.1016/j.protist.2014.08.002. Epub 2014 Aug 20. PMID: 25216472; PMCID: PMC4252602.

Zhang, H., Zhu, G., 2015. Quantitative RT-PCR assay for high-throughput screening (HTS) of drugs against the growth of Cryptosporidium parvum in vitro. Front. Microbiol. 6, 991. https://doi.org/10.3389/fmicb.2015.00991. PMID: 26441920; PMCID: PMC4585199.

Zhang, H., Guo, F., Zhu, G., 2015. *Cryptosporidium* lactate dehydrogenase is associated with the parasitophorous vacuole membrane and is a potential target for developing therapeutics. PLoS Pathog. 11 (11), e1005250 https://doi.org/10.1371/journal.ppat.1005250. PMID: 26562790; PMCID: PMC4642935.

Zhang, X., Kim, C.Y., Worthen, T., Witola, W.H., 2018. Morpholino-mediated *in vivo* silencing of *Cryptosporidium parvum* lactate dehydrogenase decreases oocyst shedding and infectivity. Int. J. Parasitol. 48 (8), 649-656. https://doi.org/10.1016/j.ijpara.2018.01.005. Epub 2018 Mar 9. PMID: 29530646; PMCID: PMC6018611.

Zhu, G., Marchewka, M.J., Woods, K.M., Upton, S.J., Keithly, J.S., 2000. Molecular analysis of a Type I fatty acid synthase in Cryptosporidium parvum. Mol. Biochem. Parasitol. 105 (2), 253-260. https://doi.org/10.1016/s0166-6851(99)00183-8. PMID: 10693747.

Zhu, G., 2004. Current progress in the fatty acid metabolism in Cryptosporidium parvum. J. Eukaryot. Microbiol. 51 (4), 381-388. https://doi.org/10.1111/j.1550-7408.2004.tb00384.x. PMID: 15352319.

Zhu, G., Yin, J., Cuny, G.D., 2021. Current status and challenges in drug discovery against the globally important zoonotic cryptosporidiosis. Animal Diseases 1, 3. https://doi.org/10.1186/s44149-021-00002-y.